"V体育安卓版" Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2017 Sep 6;25(9):2214-2224.
doi: 10.1016/j.ymthe.2017.05.012. Epub 2017 Jun 9.

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma (V体育2025版)

Andras Heczey  1 , Chrystal U Louis  2 , Barbara Savoldo  3 , Olga Dakhova  4 , April Durett  4 , Bambi Grilley  4 , Hao Liu  5 , Mengfeng F Wu  5 , Zhuyong Mei  4 , Adrian Gee  4 , Birju Mehta  4 , Huimin Zhang  4 , Nadia Mahmood  6 , Haruko Tashiro  4 , Helen E Heslop  4 , Gianpietro Dotti  3 , Cliona M Rooney  4 , Malcolm K Brenner  4
Affiliations

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

Andras Heczey et al. Mol Ther. .

Abstract

Targeting disialoganglioside (GD2) on neuroblastoma (NB) with T cells expressing a first-generation chimeric antigen receptor (CAR) was safe, but the cells had poor expansion and long-term persistence. We developed a third-generation GD2-CAR (GD2-CAR3) and hypothesized that GD2-CAR3 T cells (CARTs) would be safe and effective. This phase 1 study enrolled relapsed or refractory NB patients in three cohorts. Cohort 1 received CART alone, cohort 2 received CARTs plus cyclophosphamide and fludarabine (Cy/Flu), and cohort 3 was treated with CARTs, Cy/Flu, and a programmed death-1 (PD-1) inhibitor. Eleven patients were treated with CARTs. The infusions were safe, and no dose-limiting toxicities occurred. CARTs were detectable in cohort 1, but the lymphodepletion induced by Cy/Flu increased circulating levels of the homeostatic cytokine interleukin (IL)-15 (p = 0. 003) and increased CART expansion by up to 3 logs (p = 0. 03). PD-1 inhibition did not further enhance expansion or persistence. Antitumor responses at 6 weeks were modest. We observed a striking expansion of CD45/CD33/CD11b/CD163+ myeloid cells (change from baseline, p = 0. 0126) in all patients, which may have contributed to the modest early antitumor responses; the effect of these cells merits further study. Thus, CARTs are safe, and Cy/Flu can further increase their expansion. VSports手机版.

Keywords: GD2-CAR; immunotherapy; neuroblastoma. V体育安卓版.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow Chart of Clinical Trial NCT01822652 Black arrow indicates GD2-CAR3 T cells expanded with IL-2 and administered after a freezing step. Yellow arrows indicate conditioning with cyclophosphamide 500 mg/m2/dose on days −4, −3, and −2 and fludarabine 30 mg/m2/dose on days −4 and −3. Green arrows indicate GD2-CAR3 T cells expanded with IL-7/15 and administered without a freezing step. Blue arrows indicate PD-1 inhibitor, pembrolizumab, given at 2 mg/kg/dose on days −1 and 21. Response to therapy evaluation was completed with 3D imaging (bone marrow testing when applicable) on week 6.
Figure 2
Figure 2
Expansion and Persistence of GD2-CAR3 T Cells after Adoptive Transfer Peripheral blood evaluation of patients infused with GD2-CAR3 T cells at indicated time points. (A) Absolute lymphocyte count (Ly/μL). (B) Expansion of GD2-CAR3 T cells in patients in cohort 1 (black) or cohorts 2 and 3 (purple) prior to week 6 response to therapy evaluation by real-time PCR; transgene copy numbers per milliliter. Lines represent median. (C) Long-term persistence of GD2-CAR3 T cells in patients treated in cohort 1 (black) or cohorts 2 and 3 (purple). (D) Peak IL-15 levels (pg/mL) in patients detected on the day of CAR T cell infusions with (cohorts 2 and 3) and without lymphodepletion (cohort 1) measured by Luminex assay. Mean with SD. (E) Peripheral blood IL-15 levels (pg/mL) in patients in cohort 1 (black) or cohorts 2 and 3 (purple). Line represents median. (F) Association of area under the curve (AUC) of GD2-CAR3 T cells’ expansion until response to therapy evaluation at week 6 and peak IL-15 levels. (A and D) Patients in cohort 1 are represented in black, cohort 2 in green, and cohort 3 in blue; each patient per cohort is represented by a different shape. ***p < 0.001, t test.
Figure 3
Figure 3
Change of Peripheral Blood Myeloid Subsets after GD2-CAR3 T Cell Infusion Peripheral blood myeloid subset composition was analyzed with multiparametric flow cytometry at indicated time points. (A) Kinetics of CD45/CD33+, HLA-DR/CD15− peripheral blood myeloid-derived suppressor cell-like (MDSC-like) subset as percentage of peripheral blood monocytes. (B) Absolute number of MDSC-like myeloid subset in peripheral blood per microliter. (C) Appearance of CD45/CD33/CD11b/CD163+ myeloid subset in a representative patient after GD2-CAR3 T cell infusion. (D) Kinetics of CD45/CD33/CD11b/CD163+ peripheral blood myeloid cell subset as percentage of peripheral blood monocytes. (E) Absolute number of CD45/CD33/CD11b/CD163+ peripheral blood myeloid cell subset per microliter. Patients in cohort 1 are represented by black shapes, cohort 2 by green shapes, and cohort 3 by blue shapes. Each shape and color combination represents a patient. *p < 0.05, t test.
Figure 4
Figure 4
Outcome of Patients Treated with GD2-CAR3 T Cells (A) Waterfall plots of the difference in Curie scores before and after therapy. (B) Kaplan-Meier survival curves of all patients. (C) Separated survival curves for patients in cohort 1 (black) and cohorts 2 and 3 (both shown in pink).
See this image and copyright information in PMC

References

    1. Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., Smith M., Anderson B., Villablanca J.G., Matthay K.K., Children’s Oncology Group Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 2010;363:1324–1334. - PMC - PubMed
    1. Cheung N.K., Cheung I.Y., Kushner B.H., Ostrovnaya I., Chamberlain E., Kramer K., Modak S. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J. Clin. Oncol. 2012;30:3264–3270. - PMC - PubMed
    1. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., Huls M.H., Liu E., Gee A.P., Mei Z. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 2008;14:1264–1270. - PMC - PubMed
    1. Dotti G., Gottschalk S., Savoldo B., Brenner M.K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 2014;257:107–126. - PMC - PubMed
    1. Rouce R.H., Sharma S., Huynh M., Heslop H.E. Recent advances in T-cell immunotherapy for haematological malignancies. Br. J. Haematol. 2017;176:688–704. - "V体育官网" PMC - PubMed

Publication types

"V体育安卓版" MeSH terms

Substances